Cargando…

The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer’s disease patients

BACKGROUND: Alterations in circadian rhythms are present in the presymptomatic stage of Alzheimer’s disease (AD), possibly contributing to its pathogenesis. However, it is unknown whether such alterations are associated with worse outcomes once individuals are diagnosed with symptomatic disease. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Targa, Adriano D. S., Benítez, Iván D., Dakterzada, Faridé, Fontenele-Araujo, John, Minguez, Olga, Zetterberg, Henrik, Blennow, Kaj, Barbé, Ferran, Piñol-Ripoll, Gerard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466995/ https://www.ncbi.nlm.nih.gov/pubmed/34563258 http://dx.doi.org/10.1186/s13195-021-00903-7

Ejemplares similares

Breathing cessation events that compose the apnea–hypopnea index are distinctively associated with the adverse outcomes in Alzheimer’s disease
por: Targa, Adriano D. S., et al.
Publicado: (2023)

Blood-based lipidomic signature of severe obstructive sleep apnoea in Alzheimer’s disease
por: Dakterzada, Farida, et al.
Publicado: (2022)

Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer’s disease
por: Dakterzada, Farida, et al.
Publicado: (2023)

Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer’s Disease
por: Dakterzada, Farida, et al.
Publicado: (2021)

Sleep health and the circadian rest-activity pattern four months after COVID-19
por: Henríquez-Beltrán, Mario, et al.
Publicado: (2022)

Clinical impact of microbleeds in patients with Alzheimer’s disease
por: Vázquez-Justes, Daniel, et al.
Publicado: (2022)

Editorial: The underlying relationship between sleep and neurodegenerative diseases
por: Piñol-Ripoll, Gerard, et al.
Publicado: (2023)

Identification and validation of endogenous control miRNAs in plasma samples for normalization of qPCR data for Alzheimer’s disease
por: Dakterzada, F., et al.
Publicado: (2020)

Sleep and circadian rest-activity pattern of critical COVID-19 survivors in the long-term: a 6-month follow-up study
por: Targa, A., et al.
Publicado: (2022)

Changes in Plasma Neutral and Ether-Linked Lipids Are Associated with The Pathology and Progression of Alzheimer’s Disease
por: Dakterzada, Farida, et al.
Publicado: (2023)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Endogenous controls and microRNA profile in female patients with obstructive sleep apnea
por: Zapater, Andrea, et al.
Publicado: (2022)

Decrease in sleep quality during COVID-19 outbreak
por: Targa, Adriano D. S., et al.
Publicado: (2020)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Association between Acute Respiratory Distress Syndrome Due to COVID-19 and Long-Term Sleep and Circadian Sleep–Wake Disorders
por: Henríquez-Beltrán, Mario, et al.
Publicado: (2023)

Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest
por: Dakterzada, Farida, et al.
Publicado: (2021)

One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury
por: Clarke, Gerard Janez Brett, et al.
Publicado: (2021)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias
por: Torres-Bondia, Francisco, et al.
Publicado: (2020)

Benzodiazepine and Z-Drug Use and the Risk of Developing Dementia
por: Torres-Bondia, Francisco, et al.
Publicado: (2021)

Proteomic blood profiling in mild, severe and critical COVID-19 patients
por: Patel, Hamel, et al.
Publicado: (2021)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study
por: Bäckström, David, et al.
Publicado: (2022)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnestic Subtypes of Mild Cognitive Impairment
por: Smailovic, Una, et al.
Publicado: (2022)

Slowing gait speed precedes cognitive decline by several years
por: Skillbäck, Tobias, et al.
Publicado: (2022)

Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study
por: Dhiman, Kunal, et al.
Publicado: (2022)

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
por: Merluzzi, Andrew P., et al.
Publicado: (2019)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cvv8fdm3b4hghn4b9pgnuppp0n